Novartis Institutes For Biomedical Research (Nibr)
Director, Business Development and Licensing
Novartis Institutes For Biomedical Research (Nibr) Feb 2017 - Nov 2017
Director Portfolio Management
Novartis Institutes For Biomedical Research (Nibr) Aug 2015 - Jan 2017
Associate Director of Portfolio Management
Novartis Institutes For Biomedical Research (Nibr) Apr 2014 - Jul 2015
Senior Investigator I
Novartis Mar 2010 - Mar 2014
Investigator Iii
Education:
University of Nebraska - Lincoln 1992 - 1997
Doctorates, Doctor of Philosophy, Biochemistry, Chemistry
Techno India College of Technology
Skills:
Drug Discovery Biochemistry Drug Development Cell Pharmaceutical Industry Molecular Biology Life Sciences Cell Biology Pharmacology Western Blotting Assay Development In Vitro Chemistry Diabetes Lifesciences Clinical Research Lead Change In Vivo
- Basel, CH - South San Francisco, US Avirup BOSE - Marlborough MA, US Jacob CHA - South San Francisco CA, US Nicole COOPER - Oakland CA, US Darren FINKELSTEIN - South San Francisco CA, US Linda GREENBAUM - Florham Park NJ, US Johannes HULL - San Francisco CA, US Susan Caroline KIRKLAND - Surrey, GB Katerina LEFTHERIS - San Mateo CA, US Maureen REILLY - Burlingame CA, US Peter TARSA - Marshfield MA, US Chinweike UKOMADU - Chestnut Hill MA, US
The invention provides a pharmaceutical combination including an αvβintegrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The additional therapeutic agent may be an SGLT1/2 inhibitor, among a diverse selection of agents. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) nonanoic acid (Compound 1) and at least one additional therapeutic agent.
Combination Treatment Of Liver Diseases Using Integrin Inhibitors
- Basel, CH - South San Francisco CA, US Avirup BOSE - Marlborough MA, US Jacob CHA - South San Francisco CA, US Nicole COOPER - Oakland CA, US Darren FINKELSTEIN - South San Francisco CA, US Linda GREENBAUM - Florham Park NJ, US Johannes HULL - San Francisco CA, US Susan Caroline KIRKLAND - Surrey, GB Katerina LEFTHERIS - San Mateo CA, US Maureen REILLY - Burlingame CA, US Peter TARSA - Marshfield MA, US Chinweike UKOMADU - Chestnut Hill MA, US
International Classification:
A61K 31/46 A61K 31/4353 A61P 1/16
Abstract:
The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).
Novel Fatty Acids And Their Use In Conjugation To Biomolecules
- Basel, CH Avirup BOSE - Marlborough MA, US Alexandra Marshall BRUCE - Cambridge MA, US Alokesh DUTTAROY - Marlborough MA, US Chikwendu IBEBUNJO - Newton MA, US Aaron KANTER - Somerville MA, US Louise Clare KIRMAN - Swampscott MA, US Changgang LOU - Somerville MA, US Aimee Richardson USERA - Winchester MA, US Ken YAMADA - Brookline MA, US Jun YUAN - Boston MA, US Frederic ZECRI - Brookline MA, US
The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:
Novel Fatty Acids And Their Use In Conjugation To Biomolecules
- Basel, CH Avirup BOSE - Marlborough MA, US Alexandra Marshall BRUCE - Cambridge MA, US Alokesh DUTTAROY - Marlborough MA, US Chikwendu IBEBUNJO - Newton MA, US Aaron KANTER - Somerville MA, US Louise Clare KIRMAN - Swampscott MA, US Changgang LOU - Somerville MA, US Aimee Richardson USERA - Winchester MA, US Ken YAMADA - Brookline MA, US Jun YUAN - Boston MA, US Frederic ZECRI - Brookline MA, US
The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:
Methods Of Treating Diabetes And Related Disorders
Avirup BOSE - Cambridge MA, US Alokesh DUTTAROY - Cambridge MA, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 38/17
Abstract:
The invention relates to methods of treating metabolic conditions, including type 2 diabetes mellitus, by administering prolactin-inducible protein (PIP) or fusion proteins, analogs or variants of PIP with altered or truncated PIP sequence, site-specific mutants, or chemically modified mutants including pharmaceutical properties comprising the same.
Novel Fatty Acids And Their Use In Conjugation To Biomolecules
David Weninger BARNES - Waban MA, US Ken YAMADA - Brookline MA, US Chikwendu IBEBUNJO - Newton MA, US Alokesh DUTTAROY - Marlborough MA, US Louis Clare KIRMAN - Swampscott MA, US Alexandra Marshall BRUCE - Cambridge MA, US Aimee Richardson USERA - Winchester MA, US Frederic ZECRI - Brookline MA, US Jun YUAN - Boston MA, US Changgang LOU - Portage MI, US Aaron KANTER - Somerville MA, US Avirup BOSE - Marlborough MA, US
The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:
Googleplus
Avirup Bose
Education:
Atomic energy central
Avirup Bose
Avirup Bose
Avirup Bose
Avirup Bose
Youtube
Na tum hum e Jaano
Video from Avirup Bose.
Duration:
3m 23s
Aaj jane ki zid na karo
Please listen this with earphone.
Duration:
6m 43s
Prof Avirup Bose on Competition Law in India ...
Prof Avirup Bose elaborates the central dilemma inherent in the functi...
Duration:
19m 6s
Network effects in India's online business: A...
Avirup Bose presents a paper, co-authored with Smriti Parsheera , whic...
Duration:
23m 1s
25 December 2022
ShareInvitation Fill my invitation code JFJMV to pick me! Your vote ca...